Clinical indications for genetic testing in familial sudden cardiac death syndromes: an HRUK position statement

Garratt, C. J.
April 2008
Heart;Apr2008, Vol. 94 Issue 4, p502
Academic Journal
The sudden unexpected death of a young person can have profound implications for the surviving family members beyond those associated with bereavement and the immediate sense of loss. Among these other sequelae may be a concern that the sudden death was caused by a genetic condition and that other family members may suffer the same fate. Increased awareness of these inherited conditions and the transfer of the techniques of genetic testing from the research laboratory into the clinical arena make it possible to identify genetically affected individuals before they have symptoms or experience sudden cardiac death. The development of such tests has been paralleled by the emergence of preventative treatments, which have amplified the clinical importance of such tests. This document provides recommendations regarding the clinical indications for these tests based on the best available evidence.


Related Articles

  • Patterns of beta-blocker intensification in ambulatory heart failure patients and short-term association with hospitalization. Allen, Larry A.; Magid, David J.; Chan Zeng; Peterson, Pamela N.; Clarke, Christina L.; Shetterly, Susan; Brand, David W.; Masoudi, Frederick A. // BMC Cardiovascular Disorders;2012, Vol. 12 Issue 1, p43 

    Background: In response to the short-term negative inotropic and chronotropic effects of β-blockers, heart failure (HF) guidelines recommend initiating β-blockers at low dose with gradual uptitration as tolerated to doses used in clinical trials. However, patterns and safety of...

  • A Validated Prediction Model for All Forms of Acute Coronary Syndrome: Estimating the Risk of 6-Month Postdischarge Death in an International Registry. Eagle, Kim A.; Lim, Michael J.; Dabbous, Omar H.; Pieper, Karen S.; Goldberg, Robert J.; Van de Werf, Frans; Goodman, Shaun G.; Granger, Christopher B.; Steg, P. Gabriel; Gore, Joel M.; Budaj, Andrzej; Avezum, Álvaro; Flather, Marcus D.; Fox, Keith A. A. // JAMA: Journal of the American Medical Association;6/9/2004, Vol. 291 Issue 22, p2727 

    Context Accurate estimation of risk for untoward outcomes after patients have been hospitalized for an acute coronary syndrome (ACS) may help clinicians guide the type and intensity of therapy. Objective To develop a simple decision tool for bedside risk estimation of 6-month mortality in...

  • A Comparison of Antiarrhythmic-Drug Therapy with Implantable Defibrillators in Patients Resuscitated from Near-Fatal Ventricular Arrhythmias.  // New England Journal of Medicine;11/27/97, Vol. 337 Issue 22, p1576 

    Background: Patients who survive life-threatening ventricular arrhythmias are at risk for recurrent arrhythmias. They can be treated with either an implantable cardioverter–defibrillator or antiarrhythmic drugs, but the relative efficacy of these two treatment strategies is unknown....

  • Getting defibriallators into the hands of the people. Flynn, Kevin // New Hampshire Business Review;10/10/2008, Vol. 30 Issue 22, p16 

    The article focuses on the capability of automated external defibrillator (AED). It mentions that Matt Keene former student of the Kimball Union Academy, is the first one who tried AED when he went into sudden cardiac arrest after football practice. It founds that AED has the ability to create...

  • Heart Failure. Jessup, Mariell; Brozena, Susan // New England Journal of Medicine;5/15/2003, Vol. 348 Issue 20, p2007 

    Discusses the medical progress in treating heart failure. Developments in the advancement of understanding heart failure; Heart failure as a costly and deadly disorder; High number of elderly patients with heart failure; Syndrome of heart failure; Management of heart failure; Treatment and...

  • Gender and heart failure: a population perspective. Mehta, P. A.; Cowie, M. R. // Heart;May2006 Supplement 3, Vol. 92, piii14 

    The article discusses the clinical trial on drug treatment for chronic heart failure which was believe by physicians to be the basis of heart failure. The U.S. National Health And Nutrition Examinations Survey (NHANES) study reported that it has an overall prevalence of approximately 2 percent...

  • Pharmacological Treatment for Heart Failure: A View From the Brain. Felder, R. B.; Yu, Y.; Zhang, Z.-H.; Wei, S.-G. // Clinical Pharmacology & Therapeutics;Aug2009, Vol. 86 Issue 2, p216 

    Systolic heart failure is a feed-forward phenomenon with devastating consequences. Impaired cardiac function is the initiating event, but central nervous system mechanisms activated by persistent altered neural and humoral signals from the periphery play an important sustaining role. Animals...

  • Digoxin Therapy for Heart Failure: An Update. Morris, Spencer A.; Hatcher, H. Floyd; Reddy, Deepa K. // American Family Physician;8/15/2006, Vol. 74 Issue 4, p613 

    Digoxin therapy has long been used to treat heart failure; however, its effectiveness was not completely known until recently. Results of the Digitalis Investigation Group trial showed that adding digoxin to standard heart failure therapy had no effect on mortality. However, adding digoxin...

  • An escalating higher energy regimen was better than a fixed lower energy regimen for defibrillation in out of hospital cardiac arrest.  // Evidence Based Medicine;Oct2007, Vol. 12 Issue 5, p142 

    The article presents the abstract and author's view on the study "BIPHASIC Trial: a randomized comparison of fixed lower versus escalating higher energy levels for defibrillation in out-of-hospital cardiac arrest." The author remarks that the study provided an overview on the optimal use of...


Read the Article


Sign out of this library

Other Topics